Phase II multicenter trial of maintenance biotherapy after induction concurrent biochemotherapy for patients with metastatic melanoma

Journal of Clinical Oncology

Volumn 27, Issue 36, 2009, Pages 6207-6212

  O'Day, Steven J ^a   Atkins, Michael B ^a   Boasberg, Peter ^a   Wang, He Jing ^a   Thompson, John A ^a   Anderson, Clay M ^a   Gonzalez, Rene ^a   Lutzky, Jose ^a   Amatruda, Thomas ^a   Hersh, Evan M ^a   Weber, Jeffrey S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANAPHYLAXIS; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INDUCTION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CANCER SURVIVOR; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LEUKOPENIA; LOW DRUG DOSE; LUNG TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; URTICARIA; ADOLESCENT; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; PATHOLOGY; REMISSION; SKIN TUMOR; SURVIVAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; REMISSION INDUCTION; SKIN NEOPLASMS; SURVIVAL ANALYSIS; VINBLASTINE; YOUNG ADULT;

EID: 74949089360     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.3075     Document Type: Article

References (29)

1. Keilholz U, Scheinbenbogen C, Tilgen W, et al: Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma: Comparison of two phase II trials. Cancer 72:607-614, 1993
2. Legha SS, Ring S, Eton O, et al: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16:1752-1759, 1998
3. Richards JM, Mehta N, Ramming K, et al: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10:1338-1343, 1992
4. Legha SS, Ring S, Bedikian A, et al: Treatment of metastatic melanoma with combined chemotherapy containing ciplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon- α. Ann Oncol 7:827-835, 1996
5. O'Day SJ, Gammon G, Boasberg PD, et al: Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 17:2752-2761, 1999
6. Atkins MB, Gallob JA, Sosman JA, et al: A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-α2B in patients with metastatic melanoma. Clin Cancer Res 8:3075-3081, 2002
7. Atkins MB: Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 12:2353s-2358s, 2006
8. Margolin KA, Liu PY, Flaherty LE, et al: Phase II study of carmustine, dacarbazine, cisplatin, and tomoxifen in advanced melanoma: A Southwest Oncology Group Study. J Clin Oncol 16:664-669, 1998
9. Keilholz U, Conradt C, Legha SS, et al: Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients. J Clin Oncol 16:2921-2929, 1998
10. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907-913, 1994
11. Khayat D, Borel C, Tourani JM, et al: Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 11:2173-2180, 1993
12. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116, 1999
13. Keilholz U, Goey SH, Punt CJ, et al: Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 15:2579-2588, 1997
14. Eton O, Legha SS, Agop BY, et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase IIII randomized Trial. J Clin Oncol 20:2045-2052, 2002
15. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17:968-975, 1999
16. Bajetta E, Del Vecchio M, Nova P, et al: Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma. Ann Oncol 17:571-577, 2006
17. Atkins MB, Hsu J, Lee S, et al: Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleulin-2 and interferon alpha-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic melanoma (E3695): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 26:5748-5754, 2008
18. Ives NJ, Stowe RL, Lorigan P, et al: Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 25:5426-5434, 2007
19. O'Day SJ, Boasberg PD, Piro L, et al: Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 8:2775-2781, 2002
20. Santoli D, Clark SC, Kreider BL, et al: Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colonystimulating factor. J Immunol 141:519-526, 1988
21. Grabstein KH, Urdal DL, Tushinski RJ, et al: Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232:506-508, 1986
22. Masucci G, Ragnhammar P, Wersall P, et al: Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A). Cancer Immunol Immunother 31:231-235, 1990
23. Schiller JH, Hank JA, Khorsand M, et al: Clinical and immunological effects of granulocytemacrophage colony-stimulating factor co-administered with interleukin 2: A phase IB study. Clin Cancer Res 2:319-330, 1996
24. de Gast GC, Klumpen HJ, Vyth-Dreese FA, et al: Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colonystimulating factor, low-dose interleukin 2, and interferon α in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res 6:1267-1272, 2000
25. Spitler LE, Grossbard ML, Ernstoff MS, et al: Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colonystimulating factor. J Clin Oncol 18:1614-1621, 2000
26. Tarhini AA, Kirkwood JM, Gooding WE, et al: Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol 25:3802-3807, 2007
27. McDermott DF, Atkins MB: More support for the judicious use of high-dose interleukin-2 in patients with advance melanoma. J Clin Oncol 25: 3791-3793, 2007
28. Korn EL, Ping-Yu l, Lee SJ, et al: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534, 2008
29. Boasberg PD, Minor DR, Hamid H, et al: Prophylactic cranial irradiation (PCI) in patients (Pts) with stage IV metastatic melanoma (MM) receiving concurrent biochemotherapy (cBCT) and maintenance biotherapy (MBT). J Clin Oncol 26:722s, 2008 (suppl; abstr 20009)